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416 The Journal of Thoracic and CardioObjective: We sought to assess postoperative outcome after pneumonectomy after
neoadjuvant therapy in patients with non–small cell lung cancer.
Methods: This retrospective study included 100 patients treated from January 1989
through December 2003 for a primary lung cancer in whom pneumonectomy had
been performed after an induction treatment. Surgical intervention had not been
considered initially for the following reasons: N2 disease (stage IIIA, n  79),
doubtful resectability (stage IIIB [T4, N0], n  19), and M1 disease (stage IV [T2,
N0, M1, solitary brain metastasis], n  2). All patients received a 2-drug platinum-
based regimen with a median of 2.5 cycles (range, 2-4 cycles), and 30 had associated
radiotherapy (30-45 Gy).
Results: There were 55 right and 45 left resections. Overall 30-day and 90-day
mortality rates were 12% and 21%, respectively. At multivariate analysis, one inde-
pendent prognostic factor entered the model to predict 30-day mortality: postoper-
ative cardiovascular event (relative risk, 45.7; 95% confidence interval, 3.7-226.7;
P .001). Four variables predicted 90-day mortality: age of more than 60 years (relative
risk, 5.06; 95% confidence interval, 1.47-17.48; P  .01), male sex (relative risk, 8.25;
95% confidence interval, 1.01-67.34; P  .049), postoperative respiratory event (rela-
tive risk, 3.64; 95% confidence interval, 1.14-9.37; P  .007), and postoperative
cardiovascular event (relative risk, 7.84; 95% confidence interval, 3.12-19.71; P 
.001). Estimated overall survivals in 90-day survivors were 35% (range, 29%-41%) and
25% (range, 19.3%-30.7%) at 3 and 5 years, respectively. At multivariate analysis, one
independent prognostic factor entered the model: pathologic stage III-IV residual
disease (relative risk, 1.89; 95% confidence interval, 1.09-3.26; P  .022).
Conclusions: Pneumonectomy after induction therapy is a high-risk procedure, the
survival benefit of which appears uncertain.
The treatment of patients with locally advanced non–small lung cancer re-mains a challenge. The current efforts relate essentially to the evaluation ofinduction therapy.1-5 The purpose of such therapy is (1) to decrease the
tumor volume and, in turn, to provide the best chances for a complete resection (R0),
leaving no identifiable residual disease, and (2) to control a potentially micrometa-
static disease in distant organs. Even if the response to the induction therapy and
survival are not rigorously correlated, it seems that improvement in survival is
mainly observed in those patients in whom the disease has been downstaged by the
preoperative treatment.6 However, this long-term benefit is of modest magnitude
and could be offset by the cumulated toxicity of combined treatment modalities. We
previously reported that surgical intervention after induction therapy was associated
with an increased operative risk,7 and many reports dealing with that issue have
been published. However, only few data are available regarding pneumonectomy,
vascular Surgery ● August 2005
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ported on small case series8-12,14,16,17 with sometimes all kinds
of lung resection and without emphasis on those patients who
received pneumonectomy.6,13,15 Moreover, the usual markers
of postoperative mortality (30-day and in-hospital mortality)
might reflect the risks of the procedure insufficiently. Indeed,
treatment-related mortality should also include all deaths
occurring as a direct consequence of a complication or
sequel of surgical intervention, whatever the delay from the
surgical procedure. In that way, 90-day mortality was used
recently to emphasize the risks of right pneumonectomy
after neoadjuvant therapy for lung cancer.18 Thus we con-
ducted this study to assess the risk/benefit ratio of combined
therapies, including pneumonectomy, in terms of 30-day
and 90-day mortality and long-term survival in patients with
non–small cell lung cancer.
Patients and Methods
Patients
The medical records of 100 consecutive patients who underwent
pneumonectomy after neoadjuvant therapy for a primary lung
cancer were reviewed for the 15-year period ranging from January
TABLE 1. Variables predicting 30 day-mortality
Variable Levels
Crude HR*
estimate
Age 60 y 1
60 y 3.05
Sex Male 2.28
Female 1
Preoperative RT Yes 1
No 1.34
Resection Standard 1
Extended 1.37
Operation EPR 1.48
IPR 1
Side of resection Right 2.65
Left 1
Bronchial suture reinforcement Yes 1
No 2.43
Pathologic stage 0, I, II 1.04
III, IV 1
PO respiratory event Yes 7.4
No 1
PO cardiovascular event Yes 45.7
No 1
PO surgical complication Yes 2.4
No 1
Blood transfusion Yes 1
No 0.01
Period of the study 1989-1997 1.04
1998-2003 1
HR, Hazard ratio; CI, confidence interval; RT, radiotherapy; EPR, extraperic
by running the model with one independent variable at a time.1989 through December 2003. Patient charts were identified by
The Journal of Thoraciscreening of a database into which data were entered prospectively
for any patient undergoing surgical intervention for thoracic ma-
lignancy at our department.
There were 83 male and 17 female subjects, whose ages ranged
from 32 to 76 years (mean, 57  10 years). Surgical intervention
had not been considered initially for the following reasons: N2
disease (IIIA, n  79), doubtful resectability (stage IIIB [T4, N0],
n  19), and M1 disease (stage IV [T2, N0, M1, solitary brain
metastasis], n  2). These 2 patients were previously operated on
for their cerebral disease.
All patients received a 2-drug platinum-based regimen. Com-
bination was done with vinorelbine in 46 patients, etoposide in 25
patients, gemcitabine in 15 patients, and paclitaxel in 14 patients.
A median of 2.5 cycles (range, 2-4 cycles) was administrated.
Thirty patients received thoracic radiotherapy with neoadjuvant
chemotherapy at doses ranging from 30 to 45 Gy.
Among the 79 patients who were considered initially to have
N2 disease, only 25 (31.6%) had pathologically proved mediasti-
nal node involvement. Other cases were staged as cN2 on the basis
of computed tomographic (CT) scan findings only. None of these
patients had a positron emission tomographic scan because this
technology was not available routinely in our city before June
2004. Similarly, the diagnosis of a cT4 N0 disease (n  19) was
5% CI P value
Adjusted HR
estimate 95% CI P value
3-11.27 .09
-17.69 .43
6-4.93 .67
0-6.26 .68
5-4.91 .52
72-9.8 .14
6-8.99 .18
3-3.21 .95
3-23.2 .001
.9-355 .001 29 3.7-226.7 .001
1
4-8.74 .2
-1.40 .07
3-3.28 .95
l route; IPR, intrapericardial route; PO, postoperative. *Estimates obtained9
0.8
0.3
0.3
0.3
0.4
0.
0.6
0.3
2.
5
0.6
0
0.3established on the basis of bronchoscopic and CT scan findings.
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mediastinoscopy to rule out N2 disease, a nonresectable medias-
tinal invasion, or both.
Histology was squamous cell carcinoma in 49 patients, adeno-
carcinoma in 34 patients, and undifferentiated carcinoma in 17
patients. Nine patients had a preoperative mediastinoscopy or a
remediastinoscopy to rule out N2 disease.
Adjuvant therapy was performed under the care of referring
physicians, and therefore no uniform protocol was used. Adjuvant
radiotherapy, chemotherapy, or associated radiochemotherapy was
administered in 18, 6, and 14 patients, respectively.
Statistical Analysis
The following variables were considered as potential prognostic
factors of 30- and 90-day mortality and survival: age (60 vs60
years), sex, postoperative stage (0, I, and II vs III and IV), type of
induction therapy (chemotherapy vs radiochemotherapy), side of
resection, type of resection (standard vs extended; intrapericardial
vs extrapericardial route), reinforcement of the bronchial suture,
postoperative respiratory event (bronchopulmonary obstruction,
atelectasis, pneumonia, postpneumonectomy edema, adult respira-
tory distress syndrome, pneumothorax in the remaining lung, or
pulmonary embolism), postoperative cardiovascular event (ar-
TABLE 2. Variables predicting 90-day mortality
Variable Levels
Crude HR*
estimate
Age 60 y 1
60 y 6.85
Sex Male 4.5
Female 1
Preoperative RT Yes 1.11
No 1
Resection Standard 1
Extended 1.64
Operation EPR 1.6
IPR 1
Side of resection Right 1.87
Left 1
Bronchial suture reinforcement Yes 1
No 1.73
Pathologic stage 0, I, II 1.13
III, IV 1
PO respiratory event Yes 3.84
No 1
PO cardiovascular event Yes 6.78
No 1
PO surgical complication Yes 2.27
No 1
Blood transfusion Yes 4.09
No 1
Period of the study 1989-1997 1
1998-2003 1.04
HR, Hazard ratio; CI, confidence interval; RT, radiotherapy; EPR, extraperic
by running the model with one independent variable at a time.rhythmias, cardiac failure [whatever the origin], myocardial infarc-
418 The Journal of Thoracic and Cardiovascular Surgery ● Augution, deep vein thrombosis, or stroke), postoperative surgical com-
plication (haemothorax, bronchopleural fistula, empyema, or
cardiac luxation), perioperative allogeneic blood transfusion, and
the period of the study (1989-1997 vs 1998-2003). Survival was
estimated by using the product limit method of Kaplan-Meier.
Univariate and multivariate analyses were performed by using the
Cox proportional hazards regression model to determine factors
potentially predicting postoperative mortality (30- and 90-day
mortality) and survival. The Cox model was used to incorporate in
the same model any explanatory variables with a P value of less
than .20. Forward stepwise procedure and likelihood ratio tests
were used to select the variables with the greatest prognostic value
(P .05). Univariate and multiple logistic regression analysis was
performed to obtain factors potentially predicting postoperative
respiratory event or cardiovascular event and to adjust the odds
ratio for each risk factor while controlling for the potential influ-
ence of others variables. This statistical analysis was performed
with the SPSS V10.0 software package (SPSS Inc, Chicago, Ill).
Results
Surgical Procedure
Two patients were operated on before the completion of
% CI P value
Adjusted HR
estimate 95% CI P value
1
-23.30 .002 5.06 1.47-17.48 .01
-32.42 .14 8.25 1.01-67.34 .049
1
5-2.76 .81
5-4.87 .38
5-3.96 .31
6-4.64 .18
-4.28 .24
8-2.67 .78
9-9.29 .003 3.64 1.14-9.37 .007
1
4-16.2 .001 7.84 3.12-19.71 .001
1
3-6.19 .11
-11.2 .006
4-2.47 .93
l route; IPR, intrapericardial route; PO, postoperative. *Estimates obtained95
2.02
0.6
0.4
0.5
0.6
0.7
0.7
0.4
1.5
2.8
0.8
1.5
0.4
ardiathe neoadjuvant treatment because of a complication
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sented 1 pneumothorax and 1 hemoptysis by tumoral
necrosis. For the 98 other patients, the surgical interven-
tion was performed from 4 to 8 weeks after the comple-
tion of medical therapy.
There were 55 right and 45 left resections. The surgical
approaches were a posterolateral thoracotomy in 88 pa-
tients, a lateral thoracotomy in 11 patients, and a sternotomy
in 1 patient. The intrapericardial route was used in 85
patients. The procedure was extended to one of the follow-
ing structures: superior vena cava (n 3), aorta (n 1), left
atrium (n  2), carina (n  4), chest wall (n  1), subcla-
vian artery (n  1), and esophagus (n  1).
The main bronchus was stapled in 81 patients and hand
sutured in 19 patients (interrupted stitches in 15 and running
sutures in 4 patients). The bronchial stump was reinforced in
57 patients with a pedicled parietal pleural flap in 25 pa-
tients, mediastinal fatty tissues from the thymic area in 14
patients, a pedicled muscle in 15 patients, and pericardium
in 3 patients, with the difference relating to operator pref-
erence only. The bronchial stump was covered 48 times on
the right side (87%) and 9 times on the left side (20%). Each
resection included an ipsilateral mediastinal lymphadenec-
TABLE 3. Variables predicting postoperative respiratory e
Variable Levels
Crude OR*
estimate
Age 60 y 1
60 y 2.45
Sex Male 1
Female 1.4
Preoperative RT Yes 1.95
No 1
Resection Standard 1
Extended 1.33
Operation EPR 1.09
IPR 1
Side of resection Right 2.73
Left 1
Bronchial suture reinforcement Yes 1
No 3.48
Pathologic stage 0, I, II 1
III, IV 1.08
PO cardiovascular event Yes 4.89
No 1
PO surgical complication Yes 1.05
No 1
Blood transfusion Yes 5.18
No 1
Period of the study 1989-1997 1
1998-2003 1.62
OR, Odds ratio; CI, confidence interval; RT, radiotherapy; EPR, extrapericar
running the model with one independent variable at a time.tomy. Complete resection (R0) was achieved in 94 patients.
The Journal of ThoraciFor the remaining patients, 2 had a macroscopic residual
tumor (R2), and 4 had a microscopic residual tumor found
on specimen analysis (R1). Postoperative pathologic study
of the specimen showed no tumor cells in 8 patients, 10
stage IA tumors, 9 stage IB tumors, 7 stage IIA tumors, 15
stage IIB tumors, 25 stage IIIA tumors, 19 stage IIIB
tumors, and 7 stage IV tumors.
Postoperative Mortality
The 30-day mortality rate was 12%. This rate according to
the right side/left side distribution was, respectively, 16.4%/
6.7% (P .14). Causes of death were as follows: postpneu-
monectomy edema–adult respiratory distress syndrome (n
 5), bronchial fistula (n  2), myocardial infarction (n 
1), pulmonary embolism occurring from a superior vena
caval graft occlusion (n  1), acute right cardiac failure (n
 1), hemorrhagic shock (n  1), and sepsis shock (n  1).
Thirty-day mortality with reference to various variables is
shown in Table 1.
The 90-day mortality rate was 21%. This rate according
to the right side/left side distribution was, respectively,
25.5%/15.5% (P  .18). Ninety-day mortality with refer-
ence to various variables is mentioned in Table 2. Causes of
% CI P value
Adjusted OR
estimate 95% CI P value
5-7.09 .09
-4.88 .6
9-5.49 .20 3.84 1.09-13.55 .04
1
3-5.40 .69
5-3.40 .88
-8.29 .08
-11.40 .04
0-2.95 .87
-14.12 .003 4 1.25-12.88 .02
1
6-2.48 .94
-17.00 .07 5.59 1.47-21.26 .012
1
9-4.41 .35
ute; IPR, intrapericardial route; PO, postoperative. *Estimates obtained byvents
95
0.8
0.4
0.6
0.3
0.3
0.9
1.06
0.4
1.69
0.4
1.58
0.5
dial rothe 9 additional deaths were as follows: recurrence disease
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patient, chronic respiratory failure in 1 patient, and un-
known in 3 patients.
The adjuvant therapy did not contribute to the 90-day
mortality because among the 21 patients who died within 3
months postoperatively, only one had adjuvant
radiotherapy.
Postoperative Respiratory Event
Nineteen patients presented with one or more postoper-
ative respiratory events of very variable gravity without
technical and surgical complication. These were repre-
sented by bronchopulmonary obstruction (n  12), atel-
ectasis (n  6), postpneumonectomy edema–adult respi-
ratory distress syndrome (n  6), pneumothorax in the
remaining lung (n  1), pulmonary embolism (n  2),
and pneumonia (n  11). Among these 11 cases of
pneumonia, there were 3 cases of cytomegalovirus-in-
duced pneumonia, the diagnosis of which had been ob-
tained on the basis of a positive viremy in addition of
positive cultures from bronchoalveolar lavage. The rela-
tionship between variables and respiratory events is
TABLE 4. Variables predicting postoperative cardiovascul
Variable Levels
Crude OR*
estimate
Age 60 y 1
60 y 2.03
Sex Male 1.10
Female 1
Preoperative RT Yes 1
No 1.49
Resection Standard 1
Extended 3.07
Operation EPR 1
IPR 1.07
Side of resection Right 1.31
Left 1
Bronchial suture reinforcement Yes 1.86
No 1
Pathologic stage 0, I, II 1
III, IV 1.06
PO respiratory event Yes 4.89
No 1
PO surgical complication Yes 1.40
No 1
Blood transfusion Yes 3.65
No 1
Period of the study 1989-1997 1
1998-2003 3.16
OR, Odds ratio; CI, confidence interval; RT, radiotherapy; EPR, extrapericar
running the model with one independent variable at a time.shown in Table 3.
420 The Journal of Thoracic and Cardiovascular Surgery ● AuguPostoperative Cardiovascular Event
Twenty-five patients experienced one or more cardiovascu-
lar events without surgical complication during the postop-
erative course. These were as follow: arrhythmia (n  19),
cardiac failure (n  3), myocardial infarction (n  1), deep
vein thrombosis (n  2), and stroke (n  2). The relation-
ship between variables and cardiovascular events is shown
in Table 4.
Postoperative Surgical Complications
Thirteen patients had a surgical complication. There were
6 hemothoraxes, 6 bronchopleural fistulas, and 1 cardiac
luxation. Seven patients required a reoperation: 5 for
bronchial fistula, 1 for cardiac luxation, and 1 for
hemothorax.
Hemorrhagic Risk
Forty-nine patients were transfused (allogeneic blood trans-
fusion) with, on average, 5  3 cell packs.
Bronchial Fistula
Six patients had an early bronchial fistula. This complication
ents
% CI P value
Adjusted OR
estimate 95% CI P value
9-5.17 .14
2-3.75 .88
3-4.21 .45
-10.22 .07
7-3.08 .89
2-3.29 .56
2-4.83 .20
3-2.61 .9
-14.12 .003 3.47 1.09-10.95 .03
1
9-5.00 .61
6-9.79 .01 2.88 0.99-8.40 .05
1
1
3-8.11 .02 3.18 1.16-8.74 .03
ute; IPR, intrapericardial route; PO, postoperative. *Estimates obtained byar ev
95
0.7
0.3
0.5
0.92
0.3
0.5
0.7
0.4
1.69
0.3
1.3
1.2
dial rorepresented 9% versus 2% of the patients who underwent a
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fistulas occurred within the first 30 days after the operation.
Two (33%) patients died, both from respiratory failure.
Six empyemas occurred in otherwise healthy dis-
charged patients within the first 3 months after the pneu-
monectomy: 1 was related to esophagopleural fistula, and
2 to were related bronchopleural fistula. The results of
esophageal and bronchial fiberoscopies were normal in
TABLE 5. Relationship between variables and 5-year surviv
therapy
Variable
No. of observ
(n  100)
Age
60 y 49
60 y 51
Sex
Male 83
Female 17
Preoperative radiotherapy
Yes 30
No 70
Resection
Standard 87
Extended 13
Operation
Extrapericardial route 15
Intrapericardial route 85
Side of resection
Right 55
Left 45
Bronchial suture reinforcement
Yes 57
No 43
Pathology stage
0, I, II 49
III, IV 51
Postoperative respiratory event
Yes 19
No 81
Postoperative cardiovascular event
Yes 25
No 75
Postoperative surgical complication
Yes 13
No 87
Blood transfusion
Yes 49
No 51
Period of the study
1989-1997 57
1998-2003 43
CI, Confidence interval.the remaining 3 patients.
The Journal of ThoraciSurvival
Survival information was obtained for all patients. At
completion of the study, 25 patients were alive, and 75
were dead. The median follow-up for the survivors was
21 months (mean, 39  7 months). Their clinical status
was as follow: alive and well (84%) and alive with
disease (16%). The cause of death was related to the
operation in 16% of cases and to the lung cancer in 49%.
for patients undergoing pneumonectomy after an induction
s 95% CI
P value5 y Lower Upper
20.8% 14.2% 27.4% .18
18.7% 12.1% 25.3%
18.3% 13.3% 23.3% .69
25.4% 13.4% 37.4%
37% 27.6% 46.4% .14
10.4% 5.9% 14.9%
21.2% 16.1% 26.3% .05
9.6% 0.7% 19.7%
6% 0.3% 11.7% .44
24.1% 18.5% 29.7%
18.9% 13% 24.8% .66
20.8% 13.6% 28%
26.7% 19.6% 33.2% .30
12.5% 7.1% 17.9%
26.3% 18.9% 33.7% .08
13.3% 7.9% 18.7%
20.5% 9.5% 31.5% .07
20.6% 14.6% 26.6%
9% 0% 18% .004
22.4% 17.4% 27.4%
7% 0% 14% .03
21.9% 16.9% 26.9%
19% 12.6% 25.4% .08
21.2% 14.5% 27.9%
20.3% 14.9% 25.7% .89
23.4% 15% 31.8%als
ationCancer-unrelated deaths accounted for 11% of all deaths.
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Among the 41 patients who experienced recurrence of
their lung cancer, 32 (78%) had distant metastases, and 9
(22%) had a locoregional recurrence as the first site of
recurrence.
Estimated overall survival rates from the date of the
operation and including the operative mortality, as well as
any cancer-related and unrelated deaths, were 27.8% (range,
22.9%-32.7%) and 19.8% (range, 15.2%-24.4%) at 3 and 5
years, respectively. Survival with reference to various vari-
TABLE 6. Relationship between variables and 5-year surv
Variable
No. of observ
(n  79)
Age
60 y 46
60 y 33
Sex
Male 63
Female 16
Preoperative radiotherapy
Yes 23
No 56
Resection
Standard 70
Extended 9
Operation
Extrapericardial route 18
Intrapericardial route 61
Side of resection
Right 41
Left 38
Bronchial suture reinforcement
Yes 43
No 36
Pathology stage
0, I, II 38
III, IV 41
Postoperative respiratory event
Yes 11
No 68
Postoperative cardiovascular event
Yes 13
No 66
Postoperative surgical complication
Yes 8
No 71
Blood transfusion
Yes 33
No 46
Period of the study
1989-1997 45
1998-2003 34
CI, Confidence value.ables is shown in Table 5. At multivariate analysis, 2
422 The Journal of Thoracic and Cardiovascular Surgery ● Auguindependent prognostic factors entered the model: postop-
erative cardiovascular event (relative risk [RR], 2.29; 95%
confidence interval [CI], 1.35-3.91; P  .002) and postop-
erative surgical complication (RR, 2.13; 95% CI, 1.16-3.91;
P  .015). Estimated overall survival rates in 90-day sur-
vivors were 35% (range, 29%-41%) and 25% (range,
19.3%-30.7%) at 3 and 5 years, respectively. This survival
with reference to various variables is shown in Table 6. At
multivariate analysis, one independent prognostic factor
entered the model: pathologic stage III-IV disease (RR,
in 90-day survivors
s 95% CI
P value5 y Lower Upper
22.1% 15.2% 29% .5
29.4% 19.2% 39.3%
24.2% 17.8% 30.6% .58
27% 14.4% 39.6%
48.5% 37.3% 59.7% .05
13.1% 7.5% 18.7%
26.4% 20.2% 32.6% .07
13.8% 1.1% 26.5%
8.3% 0.4% 16.2% .7
29.7% 23.1% 36.3%
25.6% 17.8% 33.4% .74
24.7% 16.4% 33%
35.6% 26.6% 44.6% .05
14.9% 8.5% 21.3%
34.1% 24.9% 43.3% .01
16.6% 10.1% 23.1%
37% 18.2% 45.8% .95
24.6% 18.7% 30.5%
19.1% 2.5% 35.7% .91
25.5% 19.5% 31.5%
12.5% 0.8% 24.2% .14
27% 20.8% 33.2%
28.2% 19.2% 37.2% .85
23.5% 16.2% 30.8%
25.7% 19.1% 32.3% .88
23.4% 19.5% 40.3%ivals
ation1.89; 95% CI, 1.09-3.26; P  .022).
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Thirty-day mortality observed in this series (12%) is in line
with internationally reported data on lung cancer surgery in
the setting of induction therapy.10,12,16,18 It is also in accor-
dance with the risk of pneumonectomy as estimated from
nationwide data, including in high-volume hospitals
(10.7%), that is considerably higher than those typically
reported.20 However, this rate seems higher than what is
currently reported after an operation alone by single insti-
tutions or multicenter databases,21-23 suggesting an in-
creased risk caused by the preoperative oncologic therapy.
Neither 30-day nor 90-day mortality rates improved with
time in our experience. Unsurprisingly, the spectrum of
major complications included various surgical, as well as
medical, complications. However, our results show that
surgical complications were not the most determining
causes of fatality in contrast with cardiopulmonary compli-
cations. Indeed, cardiac and pulmonary events occurring in
the absence of a concomitant surgical complication were
shown to be strong and independent predictors of mortality.
Multivariate analyses suggest that both events were often
associated concurrently or sequentially and correlated with
allogeneic blood transfusions. Because blood requirements
after major operations mainly depend on preoperative he-
moglobin levels,24 it might be anticipated that induction
therapy and anemia logically increase these needs. This fact
is of clinical relevance because data on transfusion therapy
have not always been favorable, particularly in the areas of
postoperative infection, systemic inflammatory response
syndrome, multiple organ failure, and finally mortality. Fur-
thermore, the risk of infection transmission now includes
both existing and emerging pathogens. Of note, some pa-
tients had a well-documented viral pneumonia, a cause that
is not common after surgical intervention alone. This fact
also suggests an immunosuppressive side effect induced by
the preoperative treatment. Cardiac events appeared to be
more frequent in the recent period of the study. One might
hypothesize that such complications strongly depend on the
preoperative cardiac status, and this observation becomes
consistent with the constant aging of the surgical population
and its related comorbidities.
Even if it did not reach statistical significance, there was
an obvious difference according to the side of the procedure,
with a 2-fold increase of the operative risk for right pneu-
monectomy. The same excess of 30-day mortality after right
pneumonectomy after induction therapy has been already
reported by Sloan Kettering Memorial18 and might be ex-
plained by a magnification of the higher risk of bronchial
fistula and respiratory failure of right-sided procedures over
left-sided ones performed without any preoperative treat-
ment.25 Of concern is also the fact that the mortality rate
considered on a 90-day basis was about twice as high as that
observed within the first 30 postoperative days. Our 90-day
The Journal of Thoracimortality rate was very similar to that reported for right
pneumonectomy after induction therapy by Martin and col-
leagues.18 The majority of the 90-day deaths (57%) were
related to postoperative complications. Nevertheless, 1 of 5
patients dies from the initial tumor disease. Generally this
was represented by brain metastasis (75%). This concerned
patients in the beginning period of our study (1989-1997)
who did not have a routine brain CT scan performed as part
of the pretherapeutic workup. These patients had cerebral
edema during the early postoperative course related to un-
diagnosed brain metastases. Also, the incidence of sudden
deaths with unknown origin in otherwise healthy discharged
patients was substantial (14%). In our opinion, some of
them might have been due to pulmonary embolism, which is
a frequent cause of acute fatality after lung resection.26 This
might support the use of vitamin K antagonist in the long
run.
This study has the obvious limitations of a retrospective
study because of data collection. We mixed preoperative,
intraoperative, and postoperative variables in the analysis to
identify potential predictors of mortality. It might be ob-
jected that some potentially pertinent variables were miss-
ing, such as spirometric data. However, our selection crite-
ria for pneumonectomy have been rather standardized
during the period and led to a very homogeneous surgical
cohort from this point of view. It would have been also of
great interest to incorporate cardiac and respiratory exercise
stress testing findings, as well as comorbidity scores, or any
other clinically relevant markers as documented by the
current literature. Unfortunately, the modalities of such tests
and scores appeared or changed radically along the period,
resulting in a high amount of missing data and rendering the
analysis unsound. Obviously, postoperative variables are
not available at the moment of the patient selection for
surgical intervention. However, we opted deliberately for a
very pragmatic approach that evaluated also what kind of
early postoperative events might have been predictive of
delayed complications.
Despite controversial results of available randomized
trials,2,3 combined strategies with induction therapy are
currently applied worldwide for the management of patients
with advanced-stage NSCLC to improve survival. Indeed,
all our patients presented with a locally advanced or meta-
static disease, even if this statement was documented patho-
logically in only one third of the patients before the induc-
tion treatment. The indication and modalities of the
induction therapy were decided by the multidisciplinary
oncologic committee of our institution with the following
rationales: (1) even if there are contradictory data in the
literature regarding the value of induction therapy in stage
IIIA disease, any patient with resectable N2 disease is
considered a candidate for induction therapy, except if he or
she accepts to be enrolled in a clinical trial; (2) any T4 N0
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surgical intervention with or without induction chemother-
apy or radiochemotherapy; and (3) because there are no
clear guidelines for the treatment of patients with stage IV
disease, particularly in the setting of a completely resected
single brain metastasis, the treatment discussion remains
open. We opted to consider that the disease had been
downstaged by the neurosurgeon and that the treatment of
the lung cancer had to be based on the residual disease,
provided that N2 involvement had been ruled out by the use
of mediastinoscopy. We postulated that the overall progno-
sis of the highly selected population of patients with lung
cancer presenting with a resectable primary lung tumor and
an apparently solitary brain metastasis was at the same level
as that of patients presenting with a locally advanced dis-
ease in whom the problem is the presence of a disseminated
micrometastatic disease in almost all the cases.
Of interest is the fact that our patients experienced very
similar 3- and 5-year survival rates as those seen in cur-
rently available studies with multimodal therapies for
NSCLC. The substantial overall 5-year survival rate
(19.8%) we observed reflects patient selection comparable
with that reported worldwide.1,7,13,18,27,28 To the best of our
knowledge, however, this is the first report that deals spe-
cifically with the results of pneumonectomy in that setting.
In turn, few data are available to analyze our results com-
prehensively. The risk/benefit ratio associated with the pro-
cedure is difficult to assess. The fact that the occurrence of
postoperative complications was the single prognosticator
of long-term survival at the multivariate analysis performed
on the whole series of patients highlights the necessity to
consider first the toxicity of combined modalities. Interest-
ingly, the multivariate analysis limited to the 90-day survi-
vors disclosed downstaging as the sole prognosticator of
long-term survival in accordance with the results of recent
prospective trials.6,29,30 Thus our results strongly suggest
that postinduction restaging is of paramount importance to
avoid pneumonectomy in nonresponders.
Conclusion
Pneumonectomy after induction therapy is a high-risk pro-
cedure, the survival benefit of which appears uncertain. This
observation leads to consideration of alternative therapeutic
options, such as radiotherapy or bronchial, arterial, or both
sleeve lobectomies whenever technically possible, espe-
cially in patients with a right-sided disease for whom the
risk to die within 90 days after surgical intervention is at the
same level as the hope of cure.
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